Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings SpyGlass Pharma, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: SpyGlass Pharma, Inc.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: SpyGlass Pharma, Inc.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

SpyGlass Pharma, Inc. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

SpyGlass Pharma, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

SpyGlass Pharma, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

SpyGlass Pharma, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

-

Rating Revisions

SpyGlass Pharma, Inc. SectorUnited States

Financial revisions

-

Revenue revisions (1 year)

-

Revenue revisions (4 months)

-

EPS revisions (1 year)

-

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

-
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
753M - - - - -
90.08B
AA
32.91B
AAA
13.79B
A
9.91B - - - - -
1.97B -
1.41B -
897M
A
846M -
764M
AAA
Average 15.33B
AAA
Weighted average by Cap.
AAA
  1. Stock Market
  2. Stocks
  3. SGP Stock
  4. Ratings SpyGlass Pharma, Inc.